US President Donald Trump’s ‘Make in America’ pledge may have spooked many, but Indian pharmaceutical companies are optimistic.
Several Indian drugmakers that have large operations in the US are now pushing to acquire assets there by either investing in greenfield manufacturing facilities or through brownfield M&As.
Experts told ETthat the US tax policy, which slashed tax rates to around 21%, has certain advantages for Indian drug makers. ET has learnt that companies like Sun PharmaBSE -0.74 %, Cadila, Aurobindo and Torrent are looking to acquire manufacturing assets in the US.